Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

BH3I-1

Catalog No: tcsc5730

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Specifications

CAS No:
300817-68-9

Formula:
$C_{15}H_{14}BrNO_3S_2$

Pathway:
Apoptosis;Apoptosis

Target:
Bcl-2 Family;MDM-2/p53

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 4.1 mg/mL (10.24 mM)

Alternative Names:
BHI1;BH 3I1

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Observed Molecular Weight:
400.31

Product Description

BH3I-1 is a **Bcl-2 family** antagonist, which inhibits the binding of the **Bak** BH3 peptide to **Bcl-xL** with a $\mathbf{K_i}$ of 2.4±0.2 μM in FP assay. BH3I-1 has a $\mathbf{K_d}$ of 5.3 μM against the **p53**/**MDM2** pair.

IC50 & Target: Bcl-2[1]

Kd: 5.3 μM (p53/mDM2)[2]

In Vitro: BH3I-1, while inhibiting its reported target Bcl-2/Bim and Bcl-xL/Bim, shows significant inhibition of both the p53/hDM2 and p300/Hif-1α interactions. This surprising promiscuity, displays by a well studied compound leads to further interrogate the p53/hDM2 interaction utilizing a standard fluorescence polarization (FP) assay with purified protein. The results from the FP assay validates the split-luciferase screen and demonstrates that BH3I-1 has a K_d=5.3 μM against the p53/mDM2 pair, which is comparable to its low micromolar potency reported for the BH3 family of receptors[2]. BH3I-1 inhibits interaction between the BH3 domain and Bcl-xL. NMR analyses reveal that BH3I-1 targets the BH3-binding pocket of Bcl-xL with a K_i of 7.8±0.9 μM[3].